AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) shares shot up 5.9% on Wednesday . The company traded as high as $5.60 and last traded at $5.21. 156,115 shares were traded during trading, an increase of 895% from the average session volume of 15,685 shares. The stock had previously closed at $4.92.
AlloVir Trading Up 5.9%
The stock has a 50 day simple moving average of $5.83 and a 200-day simple moving average of $7.52. The firm has a market cap of $26.27 million, a PE ratio of -0.26 and a beta of 0.63.
AlloVir Company Profile
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
See Also
- Five stocks we like better than AlloVir
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
